Black Carin, da Silva Costa Fabricio
Department of Obstetrics and Gynaecology, University of Melbourne, Melbourne, VIC, Australia.
Monash Ultrasound for Women, 252-256 Clayton Road, Clayton, VIC, 3168, Australia.
Methods Mol Biol. 2018;1710:9-26. doi: 10.1007/978-1-4939-7498-6_2.
Preeclampsia is a relatively common pregnancy-related condition associated with serious maternal and fetal morbidity and mortality. It is now well established that anti-angiogenic sFlt1 is upregulated in preeclampsia and binds PlGF and VEGF, causing an imbalance in angiogenic factors with subsequent endothelial injury and dysfunction. Measurement of placental growth factor (PlGF) and the sFlt1/PlGF ratio have both been validated in other countries for screening and diagnosis of preeclampsia and the differentiation of preeclampsia from other hypertensive disorders of pregnancy. There are several automated, commercially available immunoassays capable of measuring PlGF and the sFlt1/PlGF ratio for preeclampsia diagnosis. Here we outline the methodology for using the Roche Cobas e 411 immunoassay platform to determine the sFlt1/PlGF ratio.
子痫前期是一种相对常见的妊娠相关疾病，与严重的母婴发病率和死亡率相关。现已明确，抗血管生成的可溶性fms样酪氨酸激酶1（sFlt1）在子痫前期中上调，并与胎盘生长因子（PlGF）和血管内皮生长因子（VEGF）结合，导致血管生成因子失衡，继而引起内皮损伤和功能障碍。在其他国家，胎盘生长因子（PlGF）及sFlt1/PlGF比值的测定均已被验证可用于子痫前期的筛查、诊断以及子痫前期与其他妊娠高血压疾病的鉴别诊断。有几种自动化的、可商购的免疫测定法能够测定PlGF及sFlt1/PlGF比值以用于子痫前期诊断。在此，我们概述了使用罗氏Cobas e 411免疫测定平台测定sFlt1/PlGF比值的方法。
